ESC Premium Access

Direct comparison of dabigatran, apixaban, rivaroxaban and edoxaban for effectiveness and safety among patients with non-valvular atrial fibrillation

Congress Presentation

About the speaker

Doctor Eue-Keun Choi

Seoul National University Hospital, Seoul (Korea (Republic of))
0 follower

8 more presentations in this session

Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis

Speaker: Professor G. Lip (Liverpool, GB)


Efficacy and safety of dronedarone by duration of atrial fibrillation history: a post-hoc analysis of the ATHENA trial

Speaker: Professor C. Blomstrom-Lundqvist (Orebro, SE)


Clinical characteristics and 1-year outcomes in atrial fibrillation patients with or without history of intracranial haemorrhage treated with edoxaban: snapshot analysis of the Global ETNA-AF program

Speaker: Professor P. Kirchhof (Hamburg, DE)


Dual antithrombotic therapy is similarly effective to triple therapy in preventing thrombotic events in patients with atrial fibrillation and acute coronary syndrome

Speaker: Professor Z. Motovska (Prague, CZ)


Use of direct oral anticoagulants in patients with atrial fibrillation having a history of intracranial hemorrhage

Speaker: Doctor T. Chao (Taipei, TW)


Access the full session

Poster Session 5 - Atrial fibrillation and oral anticoagulation 5

Speakers: Doctor E. Choi, Professor G. Lip, Professor C. Blomstrom-Lundqvist, Professor P. Kirchhof, Professor Z. Motovska...

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb